An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)

Daisuke Sakai, Narikazu Boku, Yasuhiro Kodera, Yoshito Komatsu, Masashi Fujii, Satoru Iwasa, Eiji Oki, Wasaburo Koizumi, Makio Gamoh, Kei Muro, Toshio Shimokawa, Taroh Satoh ASCO 2018, Chicago, 1-5 June 2018